Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price165.18 USD
Fair value121.65
Ethical score70.0/100
Our investment reviews on this name
2026-09-11Read Accumulation181.69-9.1% to today
2026-08-11Read Markup159.44+3.6% to today ✓
2026-07-02Read Distribution130.59+26.5% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Repligen Corporation holds its Accumulation at $165.18. The statistical read favours the buyers, held for 24 days.
As held on the ledger · 2026-09-11
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 24 days
Price at the screen
$165.18
Valuation
229.42 trailing · 62.33 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.05
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.39%
Below 33%
Interest-bearing debt is just 23.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.83%
Below 33%
Cash held in interest-bearing accounts and securities is 6.8% of assets, under the one-third limit.
Pass
Receivables
24.57%
Below 49%
Money owed to the company is 24.6% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. The price runs 26.4% above the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Premium Price for Thin Returns in Bioprocessing
Every new biologic drug needs filters and resins to scale from lab to factory. Repligen makes some of those tools, yet the shares trade at 57 times forward earnings while delivering just 7 percent profit margins and 3 percent return on equity. Revenue growth of 15 percent sounds solid until you notice the price already sits 20 percent above our fair value with no clear moat in sight.
We pass because the numbers do not support the multiple. Strong analyst targets sit at 180 dollars, but that optimism cannot hide the low capital returns or the gap between price and value. Ethical checks clear the business, which is the one clean part of the story.
Valuation risk is the real issue here. High expectations baked into the share price leave little margin if growth slows or competition intensifies. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RGEN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179.
2026-08-11Markup · changed$159.44+22.1%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 22.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179.
2026-07-18Distribution$130.59+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179.
2026-07-03Distribution$130.59+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$130.59Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
